Navigation Links
Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
Date:11/11/2008

- Milestone Marks the First Time a European Patient with Active Celiac Disease has Enrolled in a Clinical Trial for an Investigational Medication

from Alba Therapeutics -

BALTIMORE, Nov. 11 /PRNewswire/ -- Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease. Alba has enrolled and randomized the newly diagnosed patient from Spain in an eight-week Phase IIb trial with oral larazotide acetate, a tight junction regulator, for the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, while assessing improvement in the clinical signs and symptoms of celiac disease.

"These are decisive times for our desire to one day be able to offer our celiac patients a treatment that allows them to live more normal lives," said Dr. Gemma Castillejo, MD, a pediatric gastroenterologist and principal investigator in the study. Dr. Castillejo, a leading European celiac expert from the Sant Joan de Reus University Hospital in Reus, Spain added, "I believe this clinical trial has the potential to be a turning point in the search for treatments for celiac disease."

"This is a major milestone for the celiac community in Europe," stated Francisco Leon, MD, PhD, Vice President, Clinical Development and Medical Affairs of Alba. "This is Alba's sixth human trial with larazotide acetate, and we are excited to be advancing our investigational program for larazotide acetate in this important region of the world."

About Celiac Disease

Celiac disease is an inherited autoimmune disorder where gluten has been identified as the environmental trigger of the disea
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
3. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
4. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
5. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
6. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
7. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
8. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
9. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
10. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
11. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Lazarus Effect, a medical ... interventional devices to facilitate removal of blood clots, ... Trademark Office has issued a new patent (U.S. ... company,s Lazarus Cover TM and ReCover TM ... is a single-component stent-retriever (stentriever) with an integrated, ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Monitoring Market by Product, Component, Application and Geography - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... expected to witness a moderate growth as the markets ... have almost reached the saturation levels. The demand is ...
(Date:7/24/2014)... India , July 24, 2014 Consolidated ... Business Highlights   , India Business ... grew by 9.33% to Rs. 4,886.70 Mn Rest of ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... Mn , Glenmark Pharmaceuticals Limited, the research-led ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4
... Challenges Explorations to support bold, ... diseases, SEATTLE, March 3 The Bill & Melinda ... accept grant,proposals for the first funding round of Grand Challenges ... globe pursue,ideas that have never before been tested for solving ...
... Research Management,Organization (RMO), has contracted with Systems Medicine ... (CTI), to provide,research and site management services for ... myxoid liposarcoma with a (12;16),translocation. The study is ... experimental drug product, brostallicin. The trial will also ...
Cached Medicine Technology:Gates Foundation Seeks Proposals for Innovative Global Health Research 2Gates Foundation Seeks Proposals for Innovative Global Health Research 3Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial 2Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial 3
(Date:7/24/2014)... July 24, 2014 The South American air ... million in 2014 and is expected to register a CAGR ... spends mainly on tackling internal security issues like drug trafficking. ... 75% share in the air and missile defense radar market. ... promising future in the market for radar systems in terms ...
(Date:7/24/2014)... The National Resident Matching Program (NRMP) ... new version of its smartphone app, The MATCH Program ... participating in NRMP’s Main Residency Match® and Specialties Matching ... program information during the interview process and develop program ... order lists. Rank order lists are used by ...
(Date:7/24/2014)... Indianapolis* VxP Pharma Services announced today ... include process development and commercial manufacturing for ... offered by VxP now include:, ...     Sterile Liquids and Sterile Powders , ...     Transdermal Patches ,     Animal Health ...
(Date:7/24/2014)... July 24, 2014 Becker's Hospital Review ... Hospitals and Health Systems With Great Oncology Programs." Organizations ... terms of quality patient care, cancer outcomes and research. ... for inclusion based on rankings and awards they have ... awards were considered as part of the criteria for ...
(Date:7/24/2014)... Dr. Kwame Bawuah Edusei, a diplomat, entrepreneur, medical ... to the youth to persevere in their endeavors to ... the youth to stay away from social vices and ... will afford you the opportunity of acquiring life surviving ... in your career path.” Professionals in the fields of ...
Breaking Medicine News(10 mins):Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 2Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 3Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 4Health News:South America Air and Missile Defense Radar Market is Expected to Reach $340 Million in 2020 - New Report by MicroMarket Monitor 5Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 3Health News:VxP Pharma Expands Commercial Service Offering 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2
... critical levels compelled the Iranian Government to declare two ... country will remain closed on// 7 and 8 December ... Tehran have already been closed down by the Government, ... problems have been advised to remain indoors. ...
... persistent pain may be increased by an inflamed injury, according ... even after it has disappeared//. Several million Canadians are reported ... has published the study. The NR2B proteins in mice are ... to imprint upon the brain a painful response even when ...
... treatment can be given to eligible patients inclusive ... stage III colon cancer, according to the Journal ... study. The survival rates are reportedly higher with ... received chemotherapy after surgery to treat their advanced ...
... of the deadly bird flu, official reports from China has ... to be infected with the disease//. The victim hails from ... and pneumonia since November 23. ,A test done ... H5N1 infection and has a positive history of exposure to ...
... Two Chinese manufacturers who were making and selling inferior ... of several children after being fed with this fake ... estimates, up to 200 babies after being fed the ... doctors diagnosed the condition as "big head disease", where ...
... mechanism by which Hepatitis C could cause liver cancers is ... from the University of Texas have now discovered a biochemical ... between liver cancer and Hepatitis C. The link or association ... human papilloma virus (HPV), cervical cancer and genital warts. ...
Cached Medicine News:Health News:Chemotherapy Treatment Can Be Given To The Elderly also 2Health News:Bird Flu Infection Of Chinese Girl Prompts Fear Of Spread Across Asia 2Health News:Link Between Hepatitis C And Liver Cancer Unraveled By Scientists 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: